Here's Why Cassava Sciences Is Surging Today

165
17
Favorite

Here's Why Cassava Sciences Is Surging Today

The Motley Fool2021-07-22

Key Points Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

165

Report

Comment（17）

十米阳光
·2021-07-23
They don't have any item in production yet.
Reply
Like
Report
KS_Lee
·2021-07-22
Sava been surging for the past 2 days.
Reply
1
Report
Heidit
·2021-07-22
Cool
Reply
3
Report
huilly
·2021-07-22
?
Reply
5
Report
shika
·2021-07-22
?
Reply
6
Report
h20_mako
·2021-07-22
?
Reply
6
Report
joshua0111
·2021-07-22
Nice
Reply
8
Report
Fold Replies
- Showcase:
  Noce
  2021-07-22
  Reply
  Report
- h20_mako:
  ?
  2021-07-22
  Reply
  Report
yeelyn18
·2021-07-22
Cool
Reply
5
Report
Fold Replies
- joshua0111:
  nice
  2021-07-22
  Reply
  Report
- yeelyn18:
  Nice
  2021-07-22
  Reply
  Report
Whinz
·2021-07-22
Please like this comment
Reply
5
Report
wptang1
·2021-07-22
Like
Reply
7
Report
Disney168
·2021-07-22
Like pls
Reply
4
Report
Fold Replies
- JazzKhor:
  Okok
  2021-07-22
  Reply
  Report
Mtortise
·2021-07-22
food! up!
Reply
3
Report
Donokane
·2021-07-22
Woah! Care for I'ntl space station snacks anyone? Yum yum
Reply
1
Report
ShawnKoh1
·2021-07-22
Like pls
Reply
2
Report
Fold Replies
- SkySG:
  Done
  2021-07-22
  Reply
  Report
RodericK
·2021-07-22
Like
Reply
3
Report
Fold Replies
- Uta:
  Nice
  2021-07-22
  Reply
  Report
- Boo2bear:
  Like pls
  2021-07-22
  Reply
  Report
w8w8
·2021-07-22
steamed
Reply
2
Report
Fold Replies
- MarcO:
  nice
  2021-07-22
  Reply
  Report
Kimmikim
·2021-07-22
Hi
Reply
6
Report
Fold Replies
- Liha:
  Hi
  2021-07-22
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1146624774?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-22 11:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146624774","market":"us","top_or_hot":-1,"title":"Here's Why Cassava Sciences Is Surging Today","media":"The Motley Fool","content":"<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","article_id":"1146624774","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","pubTimestamp":1626926115,"sourceInfo":null,"weMediaInfo":null,"summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"translate_title":"这就是木薯科学今天风起云涌的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9,"SAVA":0.9},"content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":175089939,"gmtCreate":1626998487021,"gmtModify":1703482031415,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3475060425489605","authorIdStr":"3475060425489605"},"htmlText":"They don't have any item in production yet.","listText":"They don't have any item in production yet.","text":"They don't have any item in production yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175089939","repostId":1146624774,"repostType":2,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172378384,"gmtCreate":1626941067848,"gmtModify":1703480970869,"author":{"id":"3579578865458065","authorId":"3579578865458065","name":"KS_Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579578865458065","authorIdStr":"3579578865458065"},"htmlText":"Sava been surging for the past 2 days.&nbsp;","listText":"Sava been surging for the past 2 days.&nbsp;","text":"Sava been surging for the past 2 days.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172378384","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172306202,"gmtCreate":1626932440506,"gmtModify":1703480845317,"author":{"id":"3585567341976837","authorId":"3585567341976837","name":"Heidit","avatar":"https://static.tigerbbs.com/b15a14bcb1e7c71684448d84f3e500e7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3585567341976837","authorIdStr":"3585567341976837"},"htmlText":"Cool&nbsp;","listText":"Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172306202","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172975112,"gmtCreate":1626931583936,"gmtModify":1703480833473,"author":{"id":"3584235357352543","authorId":"3584235357352543","name":"huilly","avatar":"https://static.itradeup.com/news/b7a1fde5f6063db10091e669c2cc21f3","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3584235357352543","authorIdStr":"3584235357352543"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172975112","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172976774,"gmtCreate":1626931473998,"gmtModify":1703480831373,"author":{"id":"4087439987071390","authorId":"4087439987071390","name":"shika","avatar":"https://static.tigerbbs.com/2703029b3560eb0f973ab0afce30dedb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087439987071390","authorIdStr":"4087439987071390"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172976774","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172976607,"gmtCreate":1626931456809,"gmtModify":1703480830889,"author":{"id":"3585385530619181","authorId":"3585385530619181","name":"h20_mako","avatar":"https://static.tigerbbs.com/815dd8430435288774e9be0c03637f83","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585385530619181","authorIdStr":"3585385530619181"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172976607","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172978116,"gmtCreate":1626931292135,"gmtModify":1703480829432,"author":{"id":"3579878222573636","authorId":"3579878222573636","name":"joshua0111","avatar":"https://static.tigerbbs.com/662a143659b3954c78c2e0a2c91c466b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579878222573636","authorIdStr":"3579878222573636"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/172978116","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5291130,"gmtCreate":1626931772467,"gmtModify":1663231310245,"authorId":3578739466550787,"author":{"id":3578739466550787,"idStr":"3578739466550787","authorId":3578739466550787,"name":"Showcase","avatar":"https://static.tigerbbs.com/48864a971d3cf33ae9e4aed6b49688bc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172978116,"type":1,"supId":5291099,"prevId":0,"content":"Noce","text":"Noce","html":"Noce"},{"id":5291099,"gmtCreate":1626931451913,"gmtModify":1663231307431,"authorId":3585385530619181,"author":{"id":3585385530619181,"idStr":"3585385530619181","authorId":3585385530619181,"name":"h20_mako","avatar":"https://static.tigerbbs.com/815dd8430435288774e9be0c03637f83","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172978116,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":172943142,"gmtCreate":1626930133186,"gmtModify":1703480811242,"author":{"id":"3574914526090483","authorId":"3574914526090483","name":"yeelyn18","avatar":"https://static.tigerbbs.com/ae47c3e96729c68a0234dd22850dfe69","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574914526090483","authorIdStr":"3574914526090483"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/172943142","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5291091,"gmtCreate":1626931303524,"gmtModify":1663231307347,"authorId":3579878222573636,"author":{"id":3579878222573636,"idStr":"3579878222573636","authorId":3579878222573636,"name":"joshua0111","avatar":"https://static.tigerbbs.com/662a143659b3954c78c2e0a2c91c466b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172943142,"type":1,"supId":5291000,"prevId":0,"content":"<u>nice</u>","text":"<u>nice</u>","html":"<u>nice</u>"},{"id":5291000,"gmtCreate":1626930144409,"gmtModify":1635223945932,"authorId":3574914526090483,"author":{"id":3574914526090483,"idStr":"3574914526090483","authorId":3574914526090483,"name":"yeelyn18","avatar":"https://static.tigerbbs.com/ae47c3e96729c68a0234dd22850dfe69","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172943142,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":172954743,"gmtCreate":1626929893982,"gmtModify":1703480806181,"author":{"id":"3576167962782658","authorId":"3576167962782658","name":"Whinz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576167962782658","authorIdStr":"3576167962782658"},"htmlText":"Please like this comment","listText":"Please like this comment","text":"Please like this comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172954743","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172955233,"gmtCreate":1626929804522,"gmtModify":1703480805030,"author":{"id":"3581666796108206","authorId":"3581666796108206","name":"wptang1","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581666796108206","authorIdStr":"3581666796108206"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172955233","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172951253,"gmtCreate":1626929488272,"gmtModify":1703480799825,"author":{"id":"3581483862047878","authorId":"3581483862047878","name":"Disney168","avatar":"https://static.tigerbbs.com/2306a5f8d24ebd89f88132c5a8f1eeec","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3581483862047878","authorIdStr":"3581483862047878"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172951253","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290928,"gmtCreate":1626929553700,"gmtModify":1663231307540,"authorId":3583980018665683,"author":{"id":3583980018665683,"idStr":"3583980018665683","authorId":3583980018665683,"name":"JazzKhor","avatar":"https://static.tigerbbs.com/72c4959a5beb2fd83e1df2d25eb6a2c0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172951253,"type":1,"supId":0,"prevId":0,"content":"Okok","text":"Okok","html":"Okok"}],"langContent":"EN"},{"id":172921964,"gmtCreate":1626928690658,"gmtModify":1703480783583,"author":{"id":"4089089017455820","authorId":"4089089017455820","name":"Mtortise","avatar":"https://static.tigerbbs.com/995f4c334df1773b9e6feba90cad9972","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089089017455820","authorIdStr":"4089089017455820"},"htmlText":"food! up!","listText":"food! up!","text":"food! up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172921964","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172920679,"gmtCreate":1626928480291,"gmtModify":1703480779965,"author":{"id":"3574372584321621","authorId":"3574372584321621","name":"Donokane","avatar":"https://static.tigerbbs.com/b672fbcb32dfabc5e8ff43920dc4c61e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574372584321621","authorIdStr":"3574372584321621"},"htmlText":"Woah! Care for&nbsp;I'ntl space station snacks anyone? Yum yum","listText":"Woah! Care for&nbsp;I'ntl space station snacks anyone? Yum yum","text":"Woah! Care for I'ntl space station snacks anyone? Yum yum","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172920679","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172967558,"gmtCreate":1626928416374,"gmtModify":1703480778494,"author":{"id":"3570598542159923","authorId":"3570598542159923","name":"ShawnKoh1","avatar":"https://static.tigerbbs.com/0045c4894f8a2755b17a9e8518df4d5e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3570598542159923","authorIdStr":"3570598542159923"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172967558","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290785,"gmtCreate":1626928608815,"gmtModify":1663231302932,"authorId":3576458270994499,"author":{"id":3576458270994499,"idStr":"3576458270994499","authorId":3576458270994499,"name":"SkySG","avatar":"https://community-static.tradeup.com/news/0559926d7fb922e2866875c50f844c08","vip":1,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-6","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 3%","bigImgUrl":"https://community-static.tradeup.com/news/6fbaa8e552e02eae8e6a2ce5d6566431","smallImgUrl":"https://community-static.tradeup.com/news/98862e418516dab972bed7aaf561dec6","grayImgUrl":"https://community-static.tradeup.com/news/3a5ca933a5695ed2e862b228f6c09ee5","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.24","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5300},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172967558,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":172961179,"gmtCreate":1626927851491,"gmtModify":1703480770043,"author":{"id":"3574931303509491","authorId":"3574931303509491","name":"RodericK","avatar":"https://static.tigerbbs.com/de1bc8d18e14c9a78fd5fa391a0823ce","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3574931303509491","authorIdStr":"3574931303509491"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/172961179","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290770,"gmtCreate":1626928425087,"gmtModify":1663231304045,"authorId":3586953690582961,"author":{"id":3586953690582961,"idStr":"3586953690582961","authorId":3586953690582961,"name":"Uta","avatar":"https://static.tigerbbs.com/27eb5848beedf4bcbba5726bb52328cf","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172961179,"type":1,"supId":5290729,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"},{"id":5290729,"gmtCreate":1626927968165,"gmtModify":1663231303927,"authorId":3578969648963961,"author":{"id":3578969648963961,"idStr":"3578969648963961","authorId":3578969648963961,"name":"Boo2bear","avatar":"https://static.tigerbbs.com/209ae746c8124fe2d5f79aee784d2fcc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172961179,"type":1,"supId":0,"prevId":0,"content":"Like <u>pls</u>","text":"Like <u>pls</u>","html":"Like <u>pls</u>"}],"langContent":"EN"},{"id":172986811,"gmtCreate":1626927357233,"gmtModify":1703480758211,"author":{"id":"3575859183800572","authorId":"3575859183800572","name":"w8w8","avatar":"https://static.tigerbbs.com/1a305fe39d1c227693a64cc331afda1a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575859183800572","authorIdStr":"3575859183800572"},"htmlText":"steamed","listText":"steamed","text":"steamed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172986811","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290665,"gmtCreate":1626927578562,"gmtModify":1663231307043,"authorId":3579404034455974,"author":{"id":3579404034455974,"idStr":"3579404034455974","authorId":3579404034455974,"name":"MarcO","avatar":"https://static.tigerbbs.com/be5697566d0f1acd47a2c200cbfe60f0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172986811,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"EN"},{"id":172919718,"gmtCreate":1626926529534,"gmtModify":1703480738122,"author":{"id":"3587034039252261","authorId":"3587034039252261","name":"Kimmikim","avatar":"https://static.tigerbbs.com/5245979307e650b7f31c25334244e006","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3587034039252261","authorIdStr":"3587034039252261"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172919718","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://ttm.financial/m/news/1146624774?lang=&edition=fundamental","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290790,"gmtCreate":1626928682913,"gmtModify":1663231304141,"authorId":3580021038510346,"author":{"id":3580021038510346,"idStr":"3580021038510346","authorId":3580021038510346,"name":"Liha","avatar":"https://static.tigerbbs.com/a4ba484754a4e8fc7a7c54ab52161218","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172919718,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":165,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}